Ionis Pharmaceuticals Stock Z Score

IONS Stock

USD 33.32 0.44 1.34%

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Ionis Pharmaceuticals Piotroski F Score and Ionis Pharmaceuticals Valuation analysis.

For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.

At this time, Ionis Pharmaceuticals' Additional Paid In Capital is comparatively stable compared to the past year. Capital Lease Obligations is likely to gain to about 206.3 M in 2025, whereas Net Invested Capital is likely to drop slightly above 1.9 B in 2025. At this time, Ionis Pharmaceuticals' Research Development is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 280.9 M in 2025, despite the fact that EBIT is likely to grow to (215.9 M).

Ionis Pharmaceuticals Company Z Score Analysis

Ionis Pharmaceuticals' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

Z Score

Sum Of

5 Factors

More About Z Score | All Equity Analysis

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

Ionis Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Ionis Pharmaceuticals is extremely important. It helps to project a fair market value of Ionis Stock properly, considering its historical fundamentals such as Z Score. Since Ionis Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ionis Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ionis Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Net Receivables	Short Term Investments	Common Stock	Long Term Debt	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Investments
Total Assets		0.63	0.04	-0.64	0.94	1.0	0.32	0.75	0.62	0.61	0.96	0.41	0.89	0.38	0.93	0.77	0.89	0.92	-0.01	0.29	0.93	0.95	0.65	-0.52
Total Stockholder Equity	0.63		-0.7	-0.05	0.34	0.61	0.23	0.49	0.14	0.06	0.58	0.32	0.28	0.73	0.47	0.96	0.31	0.74	-0.09	0.24	0.76	0.66	-0.01	0.13
Net Debt	0.04	-0.7		-0.42	0.35	0.06	-0.04	-0.02	0.25	0.43	0.09	-0.1	0.34	-0.65	0.18	-0.51	0.3	-0.16	-0.01	-0.07	-0.15	0.03	0.6	-0.57
Retained Earnings	-0.64	-0.05	-0.42		-0.78	-0.66	-0.3	-0.82	-0.73	-0.53	-0.59	-0.71	-0.75	-0.16	-0.66	-0.11	-0.77	-0.57	-0.22	-0.27	-0.4	-0.48	-0.56	0.41
Total Liab	0.94	0.34	0.35	-0.78		0.95	0.31	0.72	0.68	0.71	0.92	0.37	0.96	0.16	0.91	0.51	0.95	0.81	0.03	0.28	0.81	0.87	0.79	-0.67
Total Current Assets	1.0	0.61	0.06	-0.66	0.95		0.34	0.75	0.62	0.63	0.96	0.41	0.9	0.38	0.92	0.75	0.91	0.92	0.0	0.31	0.93	0.94	0.66	-0.54
Short Term Debt	0.32	0.23	-0.04	-0.3	0.31	0.34		0.31	0.15	0.35	0.35	0.12	0.13	0.42	0.31	0.27	0.13	0.4	-0.06	1.0	0.29	0.2	0.2	-0.15
Intangible Assets	0.75	0.49	-0.02	-0.82	0.72	0.75	0.31		0.55	0.36	0.66	0.8	0.69	0.52	0.64	0.48	0.73	0.76	0.11	0.3	0.64	0.66	0.47	-0.21
Accounts Payable	0.62	0.14	0.25	-0.73	0.68	0.62	0.15	0.55		0.47	0.57	0.54	0.6	0.1	0.78	0.22	0.61	0.51	0.35	0.12	0.33	0.43	0.52	-0.5
Net Receivables	0.61	0.06	0.43	-0.53	0.71	0.63	0.35	0.36	0.47		0.58	0.07	0.67	0.09	0.62	0.24	0.65	0.51	-0.07	0.32	0.5	0.54	0.64	-0.57
Short Term Investments	0.96	0.58	0.09	-0.59	0.92	0.96	0.35	0.66	0.57	0.58		0.29	0.85	0.3	0.93	0.74	0.85	0.9	-0.19	0.32	0.9	0.92	0.65	-0.53
Common Stock	0.41	0.32	-0.1	-0.71	0.37	0.41	0.12	0.8	0.54	0.07	0.29		0.35	0.52	0.37	0.21	0.4	0.37	0.27	0.11	0.25	0.25	0.14	-0.1
Long Term Debt	0.89	0.28	0.34	-0.75	0.96	0.9	0.13	0.69	0.6	0.67	0.85	0.35		0.13	0.82	0.44	1.0	0.76	0.01	0.09	0.79	0.84	0.75	-0.61
Property Plant Equipment	0.38	0.73	-0.65	-0.16	0.16	0.38	0.42	0.52	0.1	0.09	0.3	0.52	0.13		0.27	0.6	0.18	0.49	-0.08	0.43	0.47	0.31	-0.15	0.19
Current Deferred Revenue	0.93	0.47	0.18	-0.66	0.91	0.92	0.31	0.64	0.78	0.62	0.93	0.37	0.82	0.27		0.63	0.82	0.82	0.01	0.27	0.77	0.83	0.69	-0.6
Net Tangible Assets	0.77	0.96	-0.51	-0.11	0.51	0.75	0.27	0.48	0.22	0.24	0.74	0.21	0.44	0.6	0.63		0.46	0.82	-0.12	0.27	0.87	0.8	0.2	-0.07
Long Term Debt Total	0.89	0.31	0.3	-0.77	0.95	0.91	0.13	0.73	0.61	0.65	0.85	0.4	1.0	0.18	0.82	0.46		0.77	0.02	0.09	0.79	0.84	0.72	-0.58
Capital Surpluse	0.92	0.74	-0.16	-0.57	0.81	0.92	0.4	0.76	0.51	0.51	0.9	0.37	0.76	0.49	0.82	0.82	0.77		-0.05	0.4	0.9	0.91	0.52	-0.22
Deferred Long Term Liab	-0.01	-0.09	-0.01	-0.22	0.03	0.0	-0.06	0.11	0.35	-0.07	-0.19	0.27	0.01	-0.08	0.01	-0.12	0.02	-0.05		-0.07	-0.17	-0.15	0.03	-0.12
Short Long Term Debt	0.29	0.24	-0.07	-0.27	0.28	0.31	1.0	0.3	0.12	0.32	0.32	0.11	0.09	0.43	0.27	0.27	0.09	0.4	-0.07		0.27	0.18	0.17	-0.09
Net Invested Capital	0.93	0.76	-0.15	-0.4	0.81	0.93	0.29	0.64	0.33	0.5	0.9	0.25	0.79	0.47	0.77	0.87	0.79	0.9	-0.17	0.27		0.96	0.52	-0.37
Net Working Capital	0.95	0.66	0.03	-0.48	0.87	0.94	0.2	0.66	0.43	0.54	0.92	0.25	0.84	0.31	0.83	0.8	0.84	0.91	-0.15	0.18	0.96		0.64	-0.41
Capital Stock	0.65	-0.01	0.6	-0.56	0.79	0.66	0.2	0.47	0.52	0.64	0.65	0.14	0.75	-0.15	0.69	0.2	0.72	0.52	0.03	0.17	0.52	0.64		-0.8
Long Term Investments	-0.52	0.13	-0.57	0.41	-0.67	-0.54	-0.15	-0.21	-0.5	-0.57	-0.53	-0.1	-0.61	0.19	-0.6	-0.07	-0.58	-0.22	-0.12	-0.09	-0.37	-0.41	-0.8

Click cells to compare fundamentals

To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.

Competition

Predict Ionis Pharmaceuticals

According to the company's disclosures, Ionis Pharmaceuticals has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.

Ionis Z Score Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ionis Pharmaceuticals' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ionis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Ionis Pharmaceuticals by comparing valuation metrics of similar companies.

Ionis Pharmaceuticals is currently under evaluation in z score category among its peers.

Ionis Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Ionis Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Ionis Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Ionis Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in Ionis Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Ionis Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ionis Pharmaceuticals' value.

		Shares
Orbimed Advisors, Llc	2024-09-30	2.3 M
Artisan Partners Limited Partnership	2024-09-30	2.2 M
Deep Track Capital, Lp	2024-09-30	2.2 M
Marshall Wace Asset Management Ltd	2024-09-30	1.9 M
Macquarie Group Ltd	2024-09-30	1.9 M
Clearbridge Advisors, Llc	2024-09-30	1.7 M
Bvf Inc	2024-09-30	1.5 M
Charles Schwab Investment Management Inc	2024-09-30	1.4 M
Ark Investment Management Llc	2024-09-30	1.4 M
Fmr Inc	2024-09-30	22.5 M
Vanguard Group Inc	2024-09-30	15.1 M

Ionis Fundamentals

	Return On Equity	-0.73
	Return On Asset	-0.0725
	Profit Margin	(0.45) %
	Operating Margin	(1.11) %
	Current Valuation	4.16 B
	Shares Outstanding	157.9 M
	Shares Owned By Insiders	0.85 %
	Shares Owned By Institutions	99.15 %
	Number Of Shares Shorted	10.24 M
	Price To Earning	101.16 X
	Price To Book	7.84 X
	Price To Sales	6.46 X
	Revenue	787.65 M
	Gross Profit	(114.91 M)
	EBITDA	(230.01 M)
	Net Income	(366.29 M)
	Cash And Equivalents	2.04 B
	Cash Per Share	14.36 X
	Total Debt	1.45 B
	Debt To Equity	2.00 %
	Current Ratio	8.18 X
	Book Value Per Share	4.20 X
	Cash Flow From Operations	(307.51 M)
	Short Ratio	6.49 X
	Earnings Per Share	(2.44) X
	Price To Earnings To Growth	25.70 X
	Target Price	61.32
	Number Of Employees	927
	Beta	0.39
	Market Capitalization	5.19 B
	Total Asset	2.99 B
	Retained Earnings	(1.8 B)
	Working Capital	2.19 B
	Current Asset	837 M
	Current Liabilities	148.88 M
	Net Asset	2.99 B

About Ionis Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Ionis Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ionis Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ionis Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Ionis Stock Analysis

When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Ionis Pharmaceuticals Stock Z Score

Ionis Pharmaceuticals Company Z Score Analysis

Z Score

Sum Of

5 Factors

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

Ionis Z Score Driver Correlations

Ionis Z Score Peer Comparison

Ionis Pharmaceuticals ESG Sustainability

Ionis Pharmaceuticals Institutional Holders

Ionis Fundamentals

About Ionis Pharmaceuticals Fundamental Analysis

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Ionis Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY